This is a working overview of circadian rhythm, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-04-12. Anything still debated is marked as such rather than presented as settled.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white solid | Visual inspection is not sufficient for identity. |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water. |
| Typical storage | -20 °C, desiccated, dark | Protect from repeated temperature changes. |
| Common analytical method | LC-MS or HPLC-UV | Reference standard required for comparison. |
| Common synonyms | SR9009; Stenabolic; REV-ERB agonist | Vendor naming may vary. |
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
=== Sexual orientation and gender identity === In February 2021, Gallup reported that 15.9% of American adults born between 1997 and 2002 identified as LGBT. Of those, 11.5% were bisexual while 2% said they were lesbian, gay, or transgender. Overall, a greater share American adults in Generation Z identifies as LGBT than those in previous generational cohorts. PRRI reported that up to 28% of Zoomers in America said they belonged to the LGBTQ community, significantly more than the 16% of Millennials and 7% of previous generations. Among Zoomer adults in the United States between the ages of 18 and 25, 72% identified as heterosexual, 15% as bisexual, 5% as gay or lesbian, and 8% as "other".
The clinical course of IPF can be unpredictable. IPF progression is associated with an estimated median survival time of 2 to 5 years following diagnosis. The 5-year survival for IPF ranges between 20 and 40%, a mortality rate higher than that of a number of malignancies, including colon cancer, multiple myeloma and bladder cancer. A multidimensional index and staging system has been proposed to predict mortality in IPF. The name of the index is GAP and is based on gender [G], age [A], and two lung physiology variables [P] (FVC and DLCO) that are commonly measured in clinical practice to predict mortality in IPF. The highest stage of GAP (stage III) has been found to be associated with a 39% risk of mortality at 1 year. This model has also been evaluated in IPF and other ILDs and shown good performance in predicting mortality in all main ILD subtypes. A modified ILD-GAP Index has been developed for application across ILD subtypes to provide disease-specific survival estimates. In IPF patients, the overall mortality at 5 years rate is high but the annual rate of all-cause mortality in patients with mild to moderate lung impairment is relatively low. This is the reason why change in lung function (FVC) is usually measured in 1-year clinical trials of IPF treatments rather than survival. In addition to clinical and physiological parameters to predict how rapidly patients with IPF might progress, genetic and molecular features are also associated with IPF mortality.
CH3CH2OH + NAD+ → CH3CHO + NADH + H+ This allows the consumption of alcoholic beverages, but its evolutionary purpose is probably the breakdown of alcohols naturally contained in foods or produced by bacteria in the digestive tract. Another evolutionary purpose is reversible metabolism of retinol (vitamin A), an alcohol, to retinaldehyde, also known as retinal, which is then irreversibly converted into retinoic acid, which regulates expression of hundreds of genes.
Protein Expression and Purification is a peer-reviewed scientific journal covering biotechnological research on protein production and isolation based on conventional fractionation as well as techniques employing various molecular biological procedures to increase protein expression.
Sources: en.wikipedia.org
In parallel, the US lifted sanctions imposed on Venezuelan oil trade and issued licenses for companies to trade Venezuelan oil. Since the attack, the Trump Administration has collected more than $13 billion in proceeds from Venezuelan oil sales, without financial oversight. It has used the disbursement of oil revenue as leverage against Rodríguez's government.
=== Commercial applications === According to a 2010 survey, the three primary uses of the 26,000 low-energy particle accelerators operating worldwide are radiotherapy (44%), ion implantation (41%), and industrial processing (9%). HVEC made foundational contributions to all three. The company's compact Van de Graaff generators were among the first artificial radiation sources commercially available for cancer treatment. Radiation physicist Milford Schulz called them "truly milestones in the progress of radiotherapy." The first medical linear accelerator—now the dominant technology in cancer treatment—was assembled at Stanford using a retrofitted HVEC machine. Ion implantation, pioneered at HVEC's Ion Physics Corporation, became standard practice in semiconductor manufacturing by the late 1970s. The technique enabled MOS integrated circuits that dominate modern electronics. Radiation crosslinking, developed at Electronized Chemicals Corporation, produced heat-shrink tubing and films now ubiquitous in electrical wiring and food packaging.
=== Pharmacokinetics === The bioavailability of doxylamine is 24.7% for oral administration and 70.8% for intranasal administration. The Tmax of doxylamine is 1.5 to 2.5 hours. Its elimination half-life is 10 to 12 hours (range 7 to 15 hours). Doxylamine is metabolized in the liver primarily by the cytochrome P450 enzymes CYP2D6, CYP1A2, and CYP2C9. The main metabolites are N-desmethyldoxylamine, N,N-didesmethyldoxylamine, and doxylamine N-oxide. Doxylamine is eliminated 60% in the urine and 40% in feces.
The court ruled that Potter's sentencing statement about Bakker, that "those of us who do have a religion are sick of being saps for money-grubbing preachers and priests", was evidence that the judge had injected his religious beliefs into Bakker's sentence. A sentence-reduction hearing was held on November 16, 1992, and Bakker's sentence was reduced to eight years. In August 1993, he was transferred to a minimum-security federal prison in Jesup, Georgia. Bakker was paroled in July 1994, after serving almost five years of his sentence. His son, Jay, spearheaded a letter-writing campaign to the parole board advocating leniency. Celebrity lawyer Alan Dershowitz acted as Bakker's parole attorney, having said that he "would guarantee that Mr. Bakker would never again engage in the blend of religion and commerce that led to his conviction." Bakker was released from Federal Bureau of Prisons custody on December 1, 1994, owing $6 million to the IRS.
Ultimately, the potential for different methods of droplet creation and analysis in directed evolution droplet-based microfluidic devices allows for a variability that facilitates a large population of potential candidates for directed evolution. As a method for protein engineering, directed evolution has many applications in fields from development of drugs and vaccines to the synthesis of food and chemicals. A microfluidic device was developed to identify improved enzyme production hosts (i.e., cell factories) that can be employed industrially in various fields. An artificial aldolase was further enhanced by 30-fold using droplet-based microfluidics so that its activity resembled that of naturally occurring proteins. More recently, the creation of functional oxidases has been enabled by a novel microfluidic device created by Debon et al. The droplet-based microfluidic approach to the directed evolution has a great potential for the development of a myriad of novel proteins.
Sources: en.wikipedia.org
Essentially, making it difficult for a clinician to use troponin elevation diagnostically in this patient group. After stenting and related PCI procedures, troponin levels do return to standard levels once the stent has 'settled' and is no longer causing localized cardiac muscle inflammation. In patients with non-severe asymptomatic aortic valve stenosis and no overt coronary artery disease, the increased troponin T (above 14 pg/mL) was found associated with an increased 5-year event rate of ischemic cardiac events (myocardial infarction, percutaneous coronary intervention, or coronary artery bypass surgery). Troponins are also increased in patients with heart failure, where they also predict mortality and ventricular rhythm abnormalities. They can rise in inflammatory conditions such as myocarditis and pericarditis with heart muscle involvement (which is then termed myopericarditis). Troponins can also indicate several forms of cardiomyopathy, such as dilated cardiomyopathy, hypertrophic cardiomyopathy or (left) ventricular hypertrophy, peripartum cardiomyopathy, Takotsubo cardiomyopathy, or infiltrative disorders such as cardiac amyloidosis. Heart injury with increased troponins also occurs in cardiac contusion, defibrillation and internal or external cardioversion. Troponins are commonly increased in several procedures such as cardiac surgery and heart transplantation, closure of atrial septal defects, percutaneous coronary intervention, or radiofrequency ablation.
== Release == The series was presented as a non-competitive screening in the official selection of the 71st San Sebastián International Film Festival on 29 September 2023. It debuted on Movistar Plus+ on 11 October 2023. The original broadcasting run ended on 16 November 2023, with the release of episode 7. HBO LatAm and Movistar Plus+ International agreed on a deal for the distribution of the series in Latin American territories. The series was selected to have its international premiere in a showcase at the 2024 Sundance Film Festival. Arte acquired rights for France and Germany as well as other European countries such as Switzerland, Austria, Belgium, Andorra, Monaco, and Luxembourg. Starting on 1 April 2026, Hulu and Disney+ released the series in the United States. Mubi programmed a streaming release in the United Kingdom, Canada, Turkey, the Netherlands, Germany, Austria, and Australia for 3 September 2026. At the September 2026 Iberseries & Platino Industria market, Mubi was announced to have acquired worldwide rights to the series.
=== CT === A computed tomography (CT) scan is another examination method often used for the diagnosis of Tarlov cyst. Unenhanced CT scans may show sacral erosion, asymmetric epidural fat distribution, and cystic masses that have the same density with CSF. CT Myelogram is minimally invasive, and could be employed when MRI cannot be performed on patient.
Cave 17 (Cave of the Bodhisattva Vault) is large "central pillar" cave located near Cave 14, and high up on the rock to the right of Cave 8. It was probably the main cave of the group of caves from 14 to 19, which also includes several undecorated living quarters or viharas, and was dedicated to religious services. Su Bai dates Cave 17 to the Second Stage (395–465 CE -+65), together with Cave 14. Luo and Wang date it to 465 CE +-65. Rhie attributes Cave 17 to circa 500, based on stylistic considerations. It is a "central pillar" cave, with a small, very colorful, square cella (3.80x3.90 meters; 12 x 13 feet) with a vaulted ceiling, a central pillar with two side corridors, and a back room. These caves were possibly small chapels to nearby viharas. In Cave 17, on the lower left panel of the entrance wall, appeared a Royal family, composed of the King, Queen and two young Princes. They are accompanied by monks, and men in caftan. The relief is now in the Hermitage Museum. The King wears a crown and a triple halo, with Sasanian-type royal ribbons. He wears a long white caftan decorated with small diamond designs, and has long boots. His right hand is in front of his chest, holding an incense lamp, and he holds an akinakes sword and a red bag in the left hand. The end of a long knight's sword is visible behind the first boot. The king can be identified as a Tocharian king of Kucha. His Queen wears a long robe, and his two sons, Princes, wear ornate caftan and are fair-haired.
Sources: en.wikipedia.org
Liquid chromatography–mass spectrometry is common for identity and purity checks. High-performance liquid chromatography with ultraviolet detection can also be used. Both methods require a suitable reference standard.
The solid is usually kept desiccated at -20 °C or lower and protected from light. Stock solutions are aliquoted to limit freeze–thaw cycles. Aqueous solutions are not generally recommended for long-term storage.
Laws differ by country and by intended use. It is not an approved medicine, and many vendors sell it as a research chemical. Purchasers are responsible for confirming local restrictions.
The most common approach is liquid chromatography-tandem mass spectrometry, often after extraction from blood, urine, or tissue. Ultraviolet detection and nuclear magnetic resonance spectroscopy are used mainly for reference material characterization. Isotope-labeled internal standards improve accuracy.